PRCT
PROCEPT BioRobotics CorpPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 26 ▲ PROCEPT BioRobotics disclosed its 2026 Analyst Day presentation, hig…
- Feb 26 ▲ PROCEPT BioRobotics reported Q4 2025 revenue of $76.4 million, up 12…
- Mar 5 to Mar 9 ▲ 3 days of insider buys: $9.8M by 1 insider, avg $24.48
- Mar 6 to Mar 19 ▼ 4 days of insider sells: $573.5K by 2 insiders, avg $24.69
- Mar 6 ▲ Over the past week, two executives at PROCEPT BioRobotics sold share…
- Mar 6 ▲ A significant insider trading cluster at PRCT shows substantial open…
- Jun 8 ▼ 3 insiders sell $28.5K at $28.48
- Aug 7 ▲ 1 insider buy $498.3K at $20.85
- Sep 9 ▼ 3 insiders sell $21.9K at $20.95
- Oct 7 Barclays initiates
- Nov 4 ▼ Earnings: PRCT Q3 2026 Earnings: EPS $-0.46 (-16.5% vs est)
- Nov 6 ▼ 1 insider sell $92.9K at $19.71
Signal stack
Where each data set points today.
- InsidersBULLISH
2 insiders bought $10.3M at an average $24.28. 4 insiders sold $716.7K.
- InstitutionsBULLISH
Q3 2026: 28 added (0 new), 16 trimmed or exited.
- AnalystsBULLISH
10 of 21 rate it Buy or better. Median target $23.00 (−2%).
- EstimatesRISING
Current-quarter EPS estimate −$0.254 → −$0.227 over 90 days. 2 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest +4.8% to 7.86M shares. 9.0 days to cover, ≈13.7% of shares.
- TrendUPTREND
21% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| JPMORGAN CHASE & CO | DOUBLED | $34.8M |
| BAILLIE GIFFORD & CO | ADD | $21.9M |
| MORGAN STANLEY | ADD | $17.6M |
| FEDERATED HERMES, INC. | TRIM | $15.4M |
| HRT FINANCIAL LP | DOUBLED | $13.1M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $10.6M |
| BARCLAYS PLC | ADD | $4.9M |
| UBS Group AG | TRIM | $4.7M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
21 analystsPrice is inside the target range. Median implies −2%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 6, 2026 | Truist Securities MAINTAIN | Hold |
| Nov 5, 2026 | UBS MAINTAIN | Neutral |
| Nov 5, 2026 | Leerink Partners MAINTAIN | Market Perform |
| Oct 7, 2026 | Barclays INITIATE | Overweight |
| Aug 5, 2026 | TD Cowen MAINTAIN | Buy |
| Aug 5, 2026 | Piper Sandler MAINTAIN | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Sharma Pooja Chief Strat/Marketing Officer Nov 6, 2026 | SELL | $92.9K |
Mack Michael Director Oct 2, 2026 | AWARD | 12,191 sh |
Mack Michael Director Oct 2, 2026 | AWARD | 7,727 sh |
Waters Kevin EVP, CFO Sep 9, 2026 | SELL | $7.8K |
Nouri Alaleh EVP, CLO, CORP. SEC. Sep 9, 2026 | SELL | $6.2K |
Templin Barry L EVP, Chief Technology Officer Sep 9, 2026 | SELL | $7.8K |
Waters Kevin EVP, CFO Aug 13, 2026 | AWARD | 40,851 sh |
Templin Barry L EVP, Chief Technology Officer Aug 13, 2026 | AWARD | 26,246 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.23 | -$0.28–-$0.14 | +10.9% | $119.9M |
| Next Q | -$0.43 | -$0.52–-$0.34 | -17.2% | $104.6M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
16 filings · 5 bullish · 0 bearish · 1 mixed · 10 neutral- NEUTRAL 144Nov 6, 2026
Pooja Sharma, an officer of PROCEPT BioRobotics, filed a Form 144 notice of intent to sell 4,710…
This is a mandatory sell-to-cover transaction for tax withholding, not a discretionary insider sale. No bearish signal. Monitor future Form 4 filings for any unplanned insider sales.
- NEUTRAL 8-KNov 4, 2026
The company reaffirmed its full-year 2026 revenue guidance of $390M-$410M and its adjusted EBITDA…
Revenue slightly missed consensus while EPS missed by $0.07, but the company reaffirmed full-year guidance and showed strong procedure growth and handpiece ASP improvement. Monitor Q4 results for…
- NEUTRAL SC 13G/AOct 30, 2026
Vanguard Capital Management LLC filed an amended Schedule 13G reporting a 4.96% passive stake in…
The marginal decline below 5% is routine for a passive index manager and does not signal a change in investment thesis. Monitor the next 13F filing for Vanguard's full portfolio positioning in PRCT.
- NEUTRAL 8-KOct 2, 2026
PROCEPT BioRobotics appointed Dr. Michael Mack as an independent Class II director, expanding the…
Routine board appointment with no immediate catalyst. Monitor for any future committee assignments or strategic shifts in the surgical robotics space given Dr. Mack's FDA and cardiothoracic expertise.
All PRCT filing & press-release reports (16)
- 144 reportNov 6, 2026
- 8-K reportNov 4, 2026
- SC 13G/A reportOct 30, 2026
- 8-K reportOct 2, 2026
- 8-K reportSep 24, 2026
- INSIDER-BUY reportAug 10, 2026
- INST-CLUSTER reportJun 11, 2026
- CLUSTER reportJun 10, 2026
- CLUSTER reportJun 10, 2026
- CLUSTER reportJun 10, 2026
- CLUSTER reportMar 10, 2026
- CLUSTER reportMar 6, 2026
- CLUSTER reportMar 6, 2026
- 8-K reportMar 6, 2026
- 8-K reportFeb 26, 2026
- 8-K reportFeb 26, 2026